The toxicity of troglitazone, roziglitazone and vitamin e in human hep g2 hepatoma cells

Ball, A.J. and Tettey, J.N.A. and Grant, M.H. (2004) The toxicity of troglitazone, roziglitazone and vitamin e in human hep g2 hepatoma cells. Toxicology, 194 (3). pp. 250-251. ISSN 0300-483X (https://doi.org/10.1016/j.tox.2003.09.003)

Abstract

Troglitazone (TGZ), a member of the thiazolidinedione class of drugs used to treat type-II diabetes, has been associated with hepatotoxicity (Biswas et al., 2001). TGZ differs structurally from the newer non-hepatotoxic glitazone, rosiglitazone (RGZ), in that it contains the chromanol moiety of Vitamin E (Vit E). This study compares the toxicity of TGZ, RGZ and Vit E in human HepG2 cells

ORCID iDs

Grant, M.H. ORCID: https://orcid.org/0000-0002-7712-404X

• Share and Export
  

  ReferAtomJSONOpenURL ContextObject in SpanMPEG-21 DIDLRDF+XMLRDF+N-TriplesRefWorksHTML CitationEndNoteMultiline CSVRIS (EndNote Online, Zotero, Ref manager, etc)Data Cite XMLDublin CoreEP3 XMLASCII CitationRDF+N3METSSimple MetadataRIOXX2 XMLBibTeXOpenURL ContextObjectMODS
• Item metadata

  Item type:	Article
  ID code:	37819
  Dates:	Date Event 2004 Published
  Notes:	Abstracts of the British Toxicology Society Annual Congress 2003.
  Subjects:	Medicine > Pharmacy and materia medica
  Department:	Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Faculty of Engineering > Bioengineering
  Depositing user:	Pure Administrator
  Date deposited:	22 Feb 2012 15:41
  Last modified:	11 Nov 2024 10:05
  URI:	https://strathprints.strath.ac.uk/id/eprint/37819